RAPS on delayed Brexit26 Mar 2019
The post-Brexit regulatory environment continues to weigh heavily on the minds of regulatory professionals.
In an attempt to find a way forward - or perhaps the exit! - in Brexit negotiations, Prime Minister Theresa May has now secured an extension to the 29 March deadline. Paul Brooks, Executive Director, RAPS, comments on recent proceedings.
"Now that Prime Minister Theresa May’s request for a Brexit deadline extension has been granted, it will provide time to make needed preparations. Uncertainty about what will happen after the UK leaves the European Union has been a major concern for regulatory affairs professionals working in pharmaceutical and medical device companies since the day the result of the Brexit referendum was announced in 2016.
"Regulatory professionals provide strategies and guidance to ensure needed healthcare products continue to flow into healthcare systems and are available to patients across Europe. Clarity on how the post-Brexit EU regulatory system and a newly separate UK system will operate relative to one another is urgently needed. Regulatory strategies responding to any change take significant time and resources to implement and need to continuously address clear regulator expectations.
"Unfortunately, now more than 2 years later, many important details remain unclear. Taking additional time to hammer out important points and possibly get a deal in place can only help, but it will be critical to use the extra time productively. In the end, if UK and EU regulations, processes and procedures diverge significantly, or if the two sides fail to agree on some form of mutual recognition, it could lead to duplication of regulatory efforts, most likely resulting in increased costs, time and resourcing for manufacturers, and possibly threatening the availability of current life-saving medicines and medical technology for healthcare providers and patients, as well slowing down access to enhanced or innovative solutions.
"The post-Brexit regulatory environment continues to weigh heavily on the minds of regulatory professionals who must guide and advise companies wishing to preserve access to such products. It is one of the major topics we will be examining at the upcoming RAPS Regulatory Conference – Europe 2019, this May in Brussels with separate sessions regarding pharmaceuticals and devices in the post-Brexit era."
2019, the year that got serialization done!
17 Dec 2019
The past 12 months have been busy as many companies fought to comply with serialization regulations.Read more
Edible barcodes - it's Tru!
10 Dec 2019
Smart tags on pills set to improve supply chain security and patient adherence.Read more
US Pharmaceutical industry continues to shine according to CPhI 2019 Annual Report
9 Dec 2019
The US pharmaceutical industry continues to lead its global peers in terms of innovation and competitiveness, while still ranking high in overall growth potential despite its mature status, according to the results of a survey of 350 global pharmaceuti...Read more
UK experiences a 'baby boom' of new life sciences ventures
2 Dec 2019
Unprecedented levels of investment cited as a major force driving the expansion.Read more
UK’s life sciences sector continues to attract talent despite Brexit fear
26 Nov 2019
The largest area of growth has been within biotechnology companies, where job openings increased by 35%.Read more
Winners of the 16th Pharma Awards
11 Nov 2019
Companies and individuals from across the whole pharma supply chain recognised for their excellence and commitment.Read more
‘FDA should withdraw ANDAs’ says expert
21 Oct 2019
CPhI Worldwide's Annual Report suggests repeat offenders of regulatory infringements should be barred from importing into the US.Read more
Sanofi opens its first digitally-enabled, continuous manufacturing facility
15 Oct 2019
One of the first digital manufacturing facilities in the world to use continuous, intensified biologics production technology.Read more
EC approves its first plant-derived cannabis-based medicine
24 Sep 2019
Epidyolex (cannabidiol) approved for the treatment of seizures in patients with two rare, severe forms of childhood-onset epilepsy.Read more
Integrating glucose sensing and insulin delivery technologies
18 Sep 2019
Collaboration aims to provide a connected device experience for millions of people living with diabetes using insulin.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation